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Objective: A double blind, randomised, placebo controlled study to evaluate the safety and efficacy of
etanercept to treat adult patients with ankylosing spondylitis (AS).
Methods: Adult patients with AS at 14 European sites were randomly assigned to 25 mg injections of
etanercept or placebo twice weekly for 12 weeks. The primary efficacy end point was an improvement of
at least 20% in patient reported symptoms, based on the multicomponent Assessments in Ankylosing
Spondylitis (ASAS) response criteria (ASAS 20). Secondary end points included ASAS 50 and ASAS 70
responses and improved scores on individual components of ASAS, the Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI), acute phase reactants, and spinal mobility tests. Safety was evaluated
during scheduled visits.
Results: Of 84 patients enrolled, 45 received etanercept and 39 received placebo. Significantly more
etanercept patients than placebo patients responded at the ASAS 20 level as early as week 2, and
sustained differences were evident up to week 12. Significantly more etanercept patients reported ASAS
50 responses at all times and ASAS 70 responses at weeks 2, 4, and 8; reported lower composite and
fatigue BASDAI scores; had lower acute phase reactant levels; and had improved spinal flexion.
Etanercept was well tolerated. Most adverse events were mild to moderate; the only between-group
difference was injection site reactions, which occurred significantly more often in etanercept patients.
Conclusions: Etanercept is a well tolerated and effective treatment for reducing clinical symptoms and signs
of AS.
A
nkylosing spondylitis (AS) is an underrecognised,
debilitating disease predominantly affecting the spine
that is characterised by axial skeletal ankylosis and
inflammation at the insertions of tendons. The prevalence of
AS is most clearly described in the white population where a
link to the HLA-B27 antigen is best defined, and is believed to
be around 0.5%, with estimates ranging from 0.1% to 1.1%.1
Peripheral joints also may be affected. The disease occurs
three times more often in men than in women,2 and onset
typically occurs between 20 and 40 years of age. Although
AS advances slowly, damage to the spine is progressive and
leads to pain, fatigue, stiffness, and functional impairment.
Patients with AS often have a restricted or poor quality of life
and may face a reduced life expectancy.3–8 The socioeconomic
burden of their disease can be considerable, owing to work
disabilities and the use of healthcare/assistance resources,
and sometimes to the patient’s depressed mood or low social
functioning.1 9–13 Current therapeutic options for AS, such as
non-steroidal anti-inflammatory drugs (NSAIDs), offer tem-
porary pain relief but confer little if any clinical benefit on
spinal mobility. Disease modifying antirheumatic drugs
(DMARDs), including methotrexate and sulfasalazine, may
benefit peripheral arthritis but do not appear to affect the
spinal involvement of AS.14–17
Tumour necrosis factor (TNF) a (TNFa), is a proinflam-
matory cytokine that appears to have a key role in the
pathogenesis of AS.12 18–22 Etanercept is a fully human
recombinant protein, comprising two molecules of soluble
TNF receptor p75 and the crystallisable fragment component
of immunoglobulin G1, which specifically binds to and
neutralises TNFa.23 24 Etanercept is effective in the treatment
of other TNF related diseases, including rheumatoid arthritis
(RA), juvenile chronic arthritis, and psoriatic arthritis
(PsA).25–27 More recently, a phase 2 clinical study has shown
that etanercept reduces disease activity in patients with
spondyloarthropathies, including reactive arthritis and
AS.28–31 Similar results have been reported with infliximab,
a chimeric monoclonal antibody against TNFa.32 33
The current double blind, randomised, multicentre
European trial examined the efficacy of etanercept to treat
AS in adults, using the recently published criteria of an
international consortium of experts, the Assessments in
Ankylosing Spondylitis (ASAS) Working Group.34 Previous
etanercept trials in AS have been conducted at both North
American and European investigative sites. This study is the
first conducted exclusively at European centres. Because
there are potentially important differences between popula-
tions studied and in the way patients are treated in different
geographical locations, it was important to this study to
confirm the results of a multinational study of etanercept
that was conducted concurrently.35 These trials are the first
studies performed with anti-TNF biological agents using the
ASAS response criteria as the primary end points.
Abbreviations: AS, ankylosing spondylitis; ASAS, Assessments in
Ankylosing Spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease
Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index;
CRP, C reactive protein; DMARDs, disease modifying antirheumatic
drugs; ESR, erythrocyte sedimentation rate; NSAIDs, non-steroidal anti-
inflammatory drugs; PsA, psoriatic arthritis; RA, rheumatoid arthritis;
TNFa, tumour necrosis factor a; VAS, visual analogue scale
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PATIENTS AND METHODS
Study design
A double blind, randomised, placebo controlled study was
conducted to evaluate the efficacy and safety of etanercept
in the treatment of adult patients with active AS. The study
took place from March 2002 to August 2002 in 14 investiga-
tive centres in eight countries: Belgium, Finland, France,
Germany, Italy, The Netherlands, Spain, and the United
Kingdom. All centres received approval from their indepen-
dent ethics committees, and all patients provided written
informed consent to participate. The study included a
screening period of up to 4 weeks, followed by a 12 week
treatment period in which patients received etanercept or
placebo. Efficacy and safety evaluations were performed at
weeks 2, 4, 8, and 12.
Patients
Patients aged 18–70 years with active AS were eligible for the
study. AS was diagnosed using the modified New York
criteria.36 Disease activity was measured using a set of visual
analogue scales (VAS) on which patients rated the severity
of their symptoms from 0 (none) to 100 (most severe) in
four symptom domains: (a) spinal inflammation; (b) back
pain; (c) patient global assessment of disease activity; and
(d) physical function. Active disease was diagnosed if the
patient had an average score >30 for spinal inflammation
and a score >30 on at least two of the other three domains.
Patients were excluded if they had complete ankylosis
(fusion) of the spine; previously used TNFa inhibitors,
including etanercept; used DMARDs other than hydroxy-
chloroquine, sulfasalazine, or methotrexate within 4 weeks
of baseline; used multiple NSAIDs; used .10 mg prednisone
daily; or changed doses of NSAIDs or prednisone within
2 weeks of baseline. Patients were permitted to continue
prestudy physiotherapy.
Patients who met eligibility criteria were stratified on the
basis of concomitant DMARD use at baseline and randomly
assigned to receive etanercept or placebo. The protocol did
not require screening for tuberculosis.
Study product
Based on previous clinical trials of etanercept in patients with
RA and PsA, a 25 mg dose delivered subcutaneously twice
weekly was selected for patients with AS. Patients self
administered the product and were given individual packages
containing injection supplies and instructions for storage and
use. To preserve the integrity of the blind study, placebo and
etanercept supplies were similar in appearance.
Efficacy end points
The clinical response to etanercept was evaluated chiefly on
the basis of response criteria recommended by the ASAS
Working Group,34 which covered the same four domains used
in this study to assess disease activity at enrolment—that is,
spinal inflammation, back pain, patient global assessment,
Table 1 Efficacy end points used to assess etanercept
I. ASAS Response Criteria: improvements of at least 20%, 50%, and 70%
in at least three of these four domains:
A. Spinal inflammation: composite of two items from BASDAI—that is,
1. Duration of morning stiffness
2. Intensity of morning stiffness
B. Total back pain and nocturnal back pain (combined)
C. Patient global assessment of health
D. Functional impairment: composite score of 10 items on BASFI—that is,
1. Putting on socks without aids
2. Picking up pen from floor
3. Reaching high shelf without aids
4. Getting up from an armless chair
5. Getting off floor from back
6. Standing unsupported for at least 10 minutes
7. Climbing 12 to 15 steps without aids
8. Looking over shoulder
9. Performing a demanding activity
10. Doing a full day’s activity
II. BASDAI scores
A. Daily activity composite score
B. Scores on six separate items
1. Fatigue
2. AS pain in necks, back, or hips
3. Pain in other joints
4. Discomfort in areas tender to touch or pressure
5. Duration of morning stiffness
6. Intensity of morning stiffness
III. Levels of acute phase reactants
A. C reactive protein (CRP)
B. Erythrocyte sedimentation rate (ESR)
IV. Spinal mobility scores
A. Forward flexion (Schober’s test)
B. Chest expansion
C. Occiput to wall distance
ASAS, Assessments in Ankylosing Spondylitis; BASDAI, Bath Ankylosing
Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis
Functional Index.
Table 2 Baseline demographic and descriptive characteristics
Characteristic
Total Placebo Etanercept
(n = 84) (n = 39) (n = 45)
Age (years), mean (SD) 43.2 (10.6) 40.7 (11.4) 45.3 (9.5)*
Sex (men/women), % 79/21 77/23 80/20
Race (white/other), % 94/6 95/5 93/7
Disease duration (years), mean (SD) 12.5 (8.9) 9.7 (8.2) 15.0 (8.8)**
Concomitant use of DMARD, No (%) 32 (38) 16 (41) 16 (36)
Hydroxychloroquine 1 (1) 1 (3) 0
Methotrexate 11 (13) 5 (13) 6 (13)
Sulfasalazine 22 (26) 11 (28) 11 (24)
Concomitant use of oral NSAID, No (%) 73 (87) 33 (85) 40 (89)
Concomitant use of corticosteroid, No (%) 13 (15) 6 (15) 7 (16)
Mean scores on ASAS components:
Spinal inflammation 65.4 62.9 67.5
Nocturnal and total back pain 58.2 56.1 60.0
Patient global assessment 64.6 63.4 65.6
Functional impairment 58.8 57.2 60.2
Mean BASDAI scores overall 59.9 58.6 61.0
BASDAI scores ,40, No (%) 10 (12) 5 (13) 4 (9)
*p,0.05 versus placebo, by analysis of variance (ANOVA); **p,0.01 versus placebo, by ANOVA; one patient
in each group took more than one DMARD.
DMARD, disease modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug.
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and physical impairment. Spinal inflammation was scored as
the average of two VAS questions about the duration and
intensity of morning stiffness, taken from the previously
validated six item Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI).37 Pain was scored as the average
of two VAS questions about total back pain and nocturnal
back pain. Patient global assessment was measured by VAS.
Functional impairment was assessed by the 10 item Bath
Ankylosing Spondylitis Functional Index (BASFI), a vali-
dated VAS based composite of functional ability in patients
with AS.38 Table 1 shows details of the BASDAI and BASFI
indexes and other efficacy end points.
The primary efficacy end point was the percentage of ASAS
20 responders after 12 weeks of treatment. ASAS 20
responders were patients who reported improvements of at
least 20% and absolute improvement of at least 10 units in at
least three of the four symptom domains, with no worsening
in the remaining domain. Secondary end points included the
percentage of ASAS 20 responders at weeks 2, 4, and 8; the
percentage of patients improving 50% or more (ASAS 50) at
any visit; and the percentage improving 70% or more
(ASAS 70) at any visit. ASAS 50 and 70 responses also
required improvement in at least three domains and no
deterioration in the remaining domain. Other patient
reported end points consisted of symptom improvements in
individual ASAS domains and improvements on the compo-
site BASDAI and its individual components. Effects on acute
phase reactants were measured by tests for C reactive protein
(CRP) and erythrocyte sedimentation rate (ESR). Effects on
spinal mobility were measured by Schober’s test, chest
expansion, and occiput to wall distance.
Safety analyses
Patients were monitored for adverse events and abnormal
laboratory test results over the course of the study. Vital signs
were monitored, and standard haematology, serum chem-
istry, and urine analysis tests were evaluated. In addition,
blood samples were tested for antibody to etanercept at
baseline and at week 12, using an enzyme linked immuno-
sorbent assay (ELISA) modified from the method published
earlier.39
Statistics
Disease activity and safety analyses were based on the
intention to treat population and included all patients who
received at least one dose of the ‘‘blinded’’ test article. The
last observation carried forward technique was used to
handle missing data for continuous and ordinal end points.
Patients who withdrew from the study prematurely were
treated as non-responders at each assessment interval there-
after for ASAS and other patient reported responses. All
statistical tests were two sided. The Cochrane-Mantel-
Haenszel test, stratified by baseline DMARD use, was used
to evaluate efficacy differences between the etanercept and
placebo groups, and x2 and Breslow-Day tests were used to
evaluate direct and interactive effects of DMARDs on ASAS
responses. For safety analyses, Fisher’s exact test was used to
compare the percentage of adverse events occurring in
etanercept and placebo treated groups. Based on a previous
trial, week 12 response rates of 35% in the placebo group and
75% in the etanercept group were expected. Assuming similar
response rates, this study design provided 90% power with 40
patients in each group.
RESULTS
Study objective
This study was conducted to evaluated the safety and efficacy
of etanercept to treat adult patients with AS.
Patient recruitment and retention
A total of 84 patients were enrolled in the study; 45 were
assigned to receive etanercept and 39 were assigned to
placebo. The average age of patients was 43.2 years. Most
participants were male (79%), and the majority were white
(94%). The treatment groups had similar baseline disease
activity scores and concomitant use of DMARDs, NSAIDs,
and corticosteroids. Demographic characteristics were largely
similar, except that etanercept patients were, on average,
5 years older than placebo patients, had had AS disease for
5 years longer (table 2), and also had significantly higher
baseline CRP levels (see table 4).
Two patients treated with etanercept discontinued the
study for non-safety reasons. The first patient discontinued
after a single dose of etanercept because he did not meet the
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Figure 1 (A) Achievement of ASAS 20, by treatment group; (B)
achievement of ASAS 50, by treatment group; (C) achievement of ASAS
70, by treatment group.
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inclusion criterion of active disease, and the second patient
withdrew his consent 8 days after treatment was started.
Both patients were treated as non-responders at subsequent
times. The remaining 82 patients completed the study.
Efficacy results
Significantly more etanercept patients than placebo patients
(26 (60%) v 9 (23%); p,0.001; 95% confidence interval (CI)
17.4 to 56.4%) were ASAS 20 responders at week 12, the
primary efficacy end point. The primary end point was not
significantly affected by the concomitant use of DMARDs
(p=0.632), nor was there an interaction effect between
DMARDs and etanercept on ASAS 20 at week 12 (p=0.694).
Significant improvements in the etanercept group were
evident by week 2, the earliest assessment point, and were
sustained thereafter (fig 1A). There were also significantly
more responders in the etanercept group at the ASAS 50 level
at all visits (p,0.01) and at the ASAS 70 level at weeks 2, 4,
and 8 (p,0.05) (figs 1B and C). By week 12, nearly half of
the patients treated with etanercept improved 50% or more
on the ASAS criteria, and a quarter of them improved 70% or
more.
ASAS responses used in this study were based on the
average of total and nocturnal back pain. The ASAS Working
Group criteria, published after plans for this study were
completed, recommended using VAS for total back pain only.
Sensitivity analyses using total pain scores alone confirmed
nearly identical results to those reported here.
In addition to improved responses on the overall ASAS
criteria, etanercept patients significantly improved their
mean scores on the individual ASAS components (p,0.01
versus placebo). Scores of etanercept patients improved 43%
on both the spinal inflammation and back pain measures,
37% on patient global assessment of disease activity, and 35%
on the functional impairment index (compared with 16%,
6%, 13%, and 3% improvements, respectively, for placebo
patients; table 3). Although scores on individual components
of the BASFI are not provided in this paper, etanercept was
significantly more effective than placebo in improving nine of
10 types of functional abilities.
Scores on the BASDAI composite index and the BASDAI
fatigue component improved 44% among etanercept patients
(p,0.01 versus placebo). In addition, a post hoc analysis of
BASDAI responses showed that the percentage of etanercept
patients with BASDAI scores ,40 increased from 9% at
baseline to 71% at week 12 (fig 2).
Acute phase reactants, CRP and ESR, also significantly
decreased in etanercept patients (p,0.0001), with percentage
changes of 70% and 80%, respectively (table 4). Spinal
flexion, as measured by Schober’s test, improved in etaner-
cept treated patients but not in placebo patients (p,0.01).
Other measures of spinal mobility also improved more in
etanercept patients, but the differences were not significant.
Patients in this trial had limited peripheral joint disease.
Numbers of swollen and tender joints were 2 and 6,
respectively, for the entire group. Given the paucity of this
information, no meaningful results on peripheral joint
disease were obtained.
Safety results
Etanercept treatment was generally well tolerated. Adverse
events were mostly mild to moderate, and there were no
discontinuations for safety reasons. Treatment-emergent
adverse events reported by 5% or more of patients in either
treatment group were generally similar (table 5). As in
previous studies of etanercept, injection site reactions
occurred significantly more often in etanercept patients
(33%) than in patients receiving placebo (15%, p,0.05). No
antibodies to etanercept were detected.
Table 3 Comparison of ASAS and BASDAI Scores before and after 12 weeks of
treatment
Response measure: assessment point
Placebo Etanercept
p Value*(n = 39) (n = 45)
ASAS: Spinal inflammation
Baseline (mean) 62.9 67.5
Week 12 (% change) 52.6 (15.9) 35.6 (43.3) 0.003
ASAS: Nocturnal and total pain
Baseline (mean) 56.1 60.0
Week 12 (% change) 51.2 (6.2) 31.0 (43.1) 0.000
ASAS: Patient global assessment
Baseline (mean) 63.4 65.6
Week 12 (% change) 54.1 (12.6) 38.4 (37.0) 0.011
ASAS: Functional impairment (BASFI)
Baseline (mean) 57.2 60.2
Week 12 (% change) 53.9 (3.4) 39.6 (35.4) 0.000
BASDAI: Composite score
Baseline (mean) 58.6 61.0
Week 12 (% change) 50.1 (13.6) 33.8 (43.6) 0.001
BASDAI: Fatigue score
Baseline (mean) 59.0 68.2
Week 12 (% change) 54.8 (24.9) 38.4 (42.6) 0.000
*Differences in mean percentage change, baseline to week 12, by the Cochrane-Mantel-Haenszel test.
ASAS, Assessments in Ankylosing Spondylitis; BASFI, Bath Ankylosing Spondylitis Functional Index; BASDAI, Bath
Ankylosing Spondylitis Disease Activity Index.
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One serious adverse event was reported. An etanercept
treated patient with acute myocardial infarction underwent
angioplasty but continued in the study. The same patient
developed grade 3 abnormality of liver function test results at
the week 12 visit, which was considered to be related to
concomitant indometacin treatment. The abnormalities
resolved after indometacin was discontinued, and the patient
completed the study.
DISCUSSION
AS is a chronic inflammatory disease, often leading to
permanent spinal damage, a considerable handicap, and a
poor quality of life. Current treatments for AS are inadequate
for most patients, especially treatments for axial skeletal
involvement.
In this 12 week study, twice weekly self administered
injections of 25 mg etanercept produced rapid, significant,
and sustained improvement in multiple clinical and biologi-
cal measures of AS, regardless of concomitant DMARD use.
Patient improvements were evident at the 2 week visit and
were sustained up to the end of the study at week 12.
Notably, the only differences between the groups at baseline
were that etanercept patients were on average 5 years older,
had had AS for 5 years longer than patients receiving
placebo, and had higher baseline CRP levels. Given the
magnitude of the etanercept treatment response in this
study, it is unlikely that these baseline differences affected
the results in any significant way. Furthermore, in light of
recent analyses indicating that older patients and patients
with longer disease duration are less likely to have a major
clinical response to TNFa inhibitors,40 41 this group’s demon-
strable response to etanercept is particularly encouraging.
The finding of multiple positive effects in this study of
European patients supports the results of two other efficacy
and safety studies of etanercept to treat AS. The first was a 16
week American study, which showed that etanercept was
efficacious in the treatment of many symptoms reported by
patients with AS, including pain, vitality, and physical
function.28 The second was a 24 week multinational study
that was conducted concurrently with the present study and
included similar end points.35 When the ASAS benchmarks of
20%, 50%, and 70% improvement were used, both the current
study and the 24 week study found that etanercept treatment
was significantly better than placebo, with robust improve-
ments occurring as early as week 2.
Treatment with etanercept also improved BASDAI scores;
by week 12, 71% of etanercept treated patients achieved
BASDAI scores ,40, which the ASAS Working Group
considers as the threshold value indicating a need for anti-
TNFa treatment.42 Moreover, fatigue scores, which are felt to
be an important outcome in AS, improved significantly with
etanercept treatment.43 Because fatigue is associated not only
with disease activity and functional ability but also with
patients’ global sense of wellbeing and mental health status,44
improvement in this area may lead to a better quality of life
for patients with AS.
In the current study, CRP levels and ESR values signifi-
cantly decreased in patients taking etanercept, which may be
indicative of disease modification, not just symptomatic relief
of AS.45–48 Spinal mobility, as measured by Schober’s test,
significantly improved in etanercept treated patients, which
suggests that damage caused by AS may not be permanent.
The lack of significant between-group differences in chest
expansion and occiput to wall distances at the end of
treatment may be due to the short duration of the study and/
or the relatively small number of patients enrolled. In the
24 week study mentioned earlier, which enrolled more
patients, all three spinal mobility measures significantly
improved with etanercept treatment.35 Owing to the short
duration of this trial, the impressive therapeutic results must
interpreted with some caution. None the less, the relative
ineffectiveness of current treatments such as DMARDs and
Table 4 Comparison of acute phase reactants and spinal mobility values before and
after 12 weeks of treatment
Measurement: assessment point Placebo Etanercept p Value*
C reactive protein (mg/l) n = 39 n =45
Baseline (median) 97 154
Week 12 (% change) 117 (0.0) 40 (69.5) 0.000
Erythrocyte sedimentation rate (mm/1st h) n = 39 n =45
Baseline (median) 26.0 27.0
Week 12 (% change) 29.0 (0.0) 6.0 (79.6) 0.000
Schober’s test of spinal flexion (cm) n = 39 n =44
Baseline (mean) 2.8 2.2
Week 12 (% change) 2.7 (1.3) 2.7 (236.0) 0.009
Chest expansion (cm) n = 39 n =44
Baseline (mean) 3.9 3.3
Week 12 (% change) 4.1 (29.0) 3.8 (229.9) 0.870
Occiput to wall distance ( cm) n = 22` n = 32`
Baseline (mean) 4.6 7.3
Week 12 (% change) 4.0 (7.2) 6.2 (12.5) 0.065
*Differences in average percentage change, baseline to week 12, by the Cochrane-Mantel-Haenszel test;
negative percentage change from baseline indicates improvement; `includes only patients who had a value
greater than zero at baseline.
Table 5 Number (%) of patients with treatment emergent
adverse events or infections (occurring in >5% of patients
in either treatment group)
Adverse event
Placebo Etanercept
p Value*(n = 39) (n = 45)
Injection site reactions 6 (15) 15 (33) 0.028
Haemorrhage, injection site 4 (10) 8 (18) 0.367
Headache 4 (10) 6 (13) 0.745
Nausea 4 (10) 3 (7) 0.699
Asthenia 1 (3) 5 (11) 0.209
Vertigo 3 (8) 0 0.096
Diarrhoea 2 (5) 2 (4) 1.000
Pruritus 2 (5) 2 (4) 1.000
Pain, abdomen 2 (5) 1 (2) 0.595
Paraesthesia 2 (5) 1 (2) 0.595
Arthralgia 2 (5) 0 0.213
Haemorrhage, gastrointestinal 2 (5) 0 0.213
Injury accidental 2 (5) 0 0.213
Pain, back 2 (5) 0 0.213
Throat irritation 2 (5) 0 0.213
*Difference in occurrence, by Fisher’s exact test.
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NSAIDs is underlined by the fact that etanercept treated
patients who continued to receive these treatments enjoyed
no apparent efficacious advantage over those who were not
receiving these drugs.
The efficacy results are also consistent with those reported
for infliximab33 49; however, no antibodies to etanercept were
found in this study. The lack of etanercept immunogenicity in
this trial might be explained by the trial’s brevity, and the
frequency of etanercept antibodies after long term treatment
in patients with AS is unknown. It is noteworthy, however,
that in etanercept trials of up to 2 years in patients with RA,
the level of etanercept antibody reactivity has been reported
to be around 3%.50 51 Additionally, these results contrast with
the recent finding of a study of infliximab to treat Crohn’s
disease, in which 61% of patients produced antibodies to
infliximab after a mean of 3.9 infusions of 5 mg/kg over a
mean of 10 months. In the latter study, antibody concentra-
tions >8.0 mg/ml significantly reduced serum concentrations
of infliximab, which in turn significantly decreased the
duration of treatment response.52
Etanercept was well tolerated in adult patients with AS.
Although approximately one third of patients had injection
site reactions, no serious infections occurred, and no patients
withdrew because of these reactions or other adverse events.
Etanercept’s safety profile was similar to that seen in patients
with RA and PsA. Although pharmacokinetic measures from
the current study are not shown in this article, a separate
analysis of clearance and steady state trough concentrations
showed that etanercept’s pharmacokinetic profile in patients
with AS was similar to that in patients with RA53; thus, it
appears that the disposition of etanercept is unaltered by the
AS disease state.
As noted above the socioeconomic burden of AS can be
considerable. Thus, the relatively higher cost of etanercept
treatment compared with less efficacious treatments should
be weighed against the costs of AS disease.
In summary, etanercept produced a rapid and sustained
reduction of the clinical signs and symptoms of AS. Given
these results, further investigation of longer term treatment
with etanercept is warranted to further define its therapeutic
utility. The use of imaging tools also is warranted to
investigate the effects of etanercept on spinal disease, and
such tests may shed light on whether etanercept can halt the
progression of AS.
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